Osteoarthritis of the Knee or Hip
Osteoarthritis of the Hip or Knee Study Details - Click Here
Subcutaneous Tanezumab Titration Dosing Regimen in Subjects With Moderate to Severe Osteoarthritis of the Hip or Knee.
A Phase 3 Randomized, Double-blind, Placebo-controlled, Multicenter Study Of The Analgesic Efficacy And Safety Of A Dose Titration Regimen For The Subcutaneous Administration Of Tanezumab In Subjects With Osteoarthritis Of The Hip Or Knee.
The primary purpose of this study is to evaluate the efficacy of a titration arm of tanezumab in which treatment is started at a lower dose (2.5 mg) and increased to a higher dose (5 mg) at Week 8, compared to giving 2 doses of tanezumab 2.5 mg or 2 doses of placebo. The study also evaluates the safety of the treatment regimens.
Qualified participants must:
- Be 18 years of age or older
- Have arthritis in a knee or hip
- Have taken pain medication for your arthritis – Naprelan, Aleve, Noprasyn, Anaprox, Celebrex, Voltaren, Solaraze, Cambia, Zipsor, Pennsaid, flector or Cataflam
- Have not had a knee, hip or shoulder injury, or operation in the past year
Compensation for your time and travel expenses may also be provided.
Interested in participating in this study?
Completing this form in no way obligates you to participate in a clinical trial, but may result in a research member contacting you by phone or email to assess your qualification into one of our research studies.